1988, 140, 2197200. 143. Segura-Pacheco, B.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I.; Chavez, A.; Acu , C.; Salazar, A.M.; Lizano, M.; Due s-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their prospective use in cancer therapy. Clin. Cancer Res. 2003, 9, 1596603. 144. Zambrano, P.; Segura-Pacheco, B.; Perez-Cardenas, E.; Cetina, L.; Revilla-Vazquez, A.; Taja-Chayeb, L.; Chavez-Blanco, A.; Angeles, E.; Cabrera, G.; Sandoval, K.; et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, five, 44. 145. Chuang, J.C.; Yoo, C.B.; Kwan, J.M.; Li, T.W.H.IRF5-IN-1 MedChemExpress ; Liang, G.; Yang, A.S.; Jones, P.A. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2’deoxycytidine. Mol. Cancer Ther. 2005, 4, 1515520. 146. Fenster, P.E.; Comess, K.A.; Marsh, R.; Katzenberg, C.; Hager, W.D. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am. Heart J. 1983, 106, 50104. 147. Villar-Garea, A.Bakuchiol Biological Activity ; Fraga, M.F.; Espada, J.; Esteller, M. Procaine can be a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63, 4984989. 148. Lee, B.H.; Yegnasubramanian, S.; Lin, X.; Nelson, W.G. Procainamide is actually a certain inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280, 407490756. 149. Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.PMID:23514335 Cancer Res. 2006, 66, 2794800. 150. Halby, L.; Champion, C.; S amaud-Beaufort, C.; Ajjan, S.; Drujon, T.; Rajavelu, A.; Ceccaldi, A.; Jurkowska, R.; Lequin, O.; Nelson, W.G.; et al. Speedy synthesis of new DNMT inhibitors derivatives of procainamide. Chembiochem 2012, 13, 15765. 151. Lin, Y.-S.; Shaw, A.Y.; Wang, S.-G.; Hsu, C.-C.; Teng, I.-W.; Tseng, M.-J.; Huang, T.H.; Chen, C.-S.; Leu, Y.-W.; Hsiao, S.-H. Identification of novel DNA methylation inhibitors by means of a two-component reporter gene method. J. Biomed. Sci. 2011, 18, 3.Int. J. Mol. Sci. 2013,152. Fang, M.Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J.K.; Yang, C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11, 7033041. 153. Lee, W.J.; Shim, J.-Y.; Zhu, B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68, 1018030. 154. Wang, Y.; Li, Y.; Liu, X.; Cho, W.C. Genetic and epigenetic studies for figuring out molecular targets of organic product anticancer agents. Curr. Cancer Drug Targets 2013, 13, 50618. 155. Plummer, R.; Vidal, L.; Griffin, M.; Lesley, M.; de Bono, J.; Coulthard, S.; Sludden, J.; Siu, L.L.; Chen, E.X.; Oza, A.M.; et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, offered as a 7-day infusion in sufferers with advanced solid tumors. Clin. Cancer Res. 2009, 15, 3177183. 156. Klisovic, R.B.; Stock, W.; Cataland, S.; Klisovic, M.I.; Liu, S.; Blum, W.; Green, M.; Odenike, O.; Godley, L.; Burgt, J.V. et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin. Cancer Res. 2008, 14, 2444449. 2013 by the authors; licensee MDPI, Basel, Switzerland. This short article is an open acce.
